What does CUSIP 47103J105 represent in this 13F holders report?

CUSIP 47103J105 is the security identifier for JANX - Janux Therapeutics, Inc. - COMMON STOCK used to aggregate holder disclosures.

How many institutions held JANX - Janux Therapeutics, Inc. - COMMON STOCK in Q2 2021?

29 institutional investors reported JANX - Janux Therapeutics, Inc. - COMMON STOCK for Q2 2021. Use the holders table for investor-level position and value details.

Janux Therapeutics, Inc. - COMMON STOCK (JANX)

CUSIP: 47103J105

Q2 2021 13F Holders as of 30 Jun 2021

Type / Class: Equity / COMMON STOCK
Shares outstanding: 60,374,372
Total 13F shares: 24,743,225
Share change: +24,743,225
Total reported value: $614,460,000
Price per share: $24.95
Number of holders: 29
Value change: +$614,460,000
Number of buys: 29

Quarterly Holders Quick Answers

What is CUSIP 47103J105?
CUSIP 47103J105 identifies JANX - Janux Therapeutics, Inc. - COMMON STOCK in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2021

Recent filing periods for CUSIP 47103J105:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of JANX - Janux Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Bregua Corp	3/4/5	10%+ Owner	— class O/S missing	3,749,250	$22,008,098	—	15 Jun 2021	3/4/5

Institutional Holders of Janux Therapeutics, Inc. - COMMON STOCK (JANX) as of Q2 2021

As of 30 Jun 2021, Janux Therapeutics, Inc. - COMMON STOCK (JANX) was held by 29 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 24,743,225 shares. The largest 10 holders included RA CAPITAL MANAGEMENT, L.P., ORBIMED ADVISORS LLC, JANUS HENDERSON GROUP PLC, CITADEL ADVISORS LLC, FMR LLC, EcoR1 Capital, LLC, BVF INC/IL, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Samsara BioCapital, LLC, and Logos Global Management LP. This page lists 29 institutional shareholders reporting positions in this security for the Q2 2021 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2021 vs Q4 2025 Across Filers

Q4 2025 holders

172

Q2 2021 holders

Holder diff

-143

Investor	Q4 2025 Shares	Q2 2021 Shares	Share Diff	Share Chg %	Q4 2025 Value $	Q2 2021 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.